SMO and osteosarcoma: Our current study clearly shows that the canonical pathway plays a critical role in Ptch1 deficiency-induced enchondroma and osteosarcoma formation, as inhibitors for Smo or Gli1/2, which are developed as candidate drugs to treat cartilage and bone tumors (Amakye et al., 2013), suppressed tumorigenesis.